Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 1106

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 1106
---
 (loss) – foreign currency translation 
     224  
     (100)
  
    Total comprehensive loss 
    $(41,858) 
    $(30,108)

See accompanying notes to these consolidated financial
statements. 

F-4

INMUNE BIO INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’
EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In thousands, except share amounts)

    Common Stock  
    Additional Paid-In  
    Accumulated Other Comprehensive  
    Accumulated  
    Total Stockholders’ 

    Shares  
    Amount  
    Capital  
    Income (loss)  
    Deficit  
    Equity 
  
    Balance as of January 1, 2023 
     17,945,995  
    $18  
    $151,799  
    $(699) 
    $(91,014) 
    $60,104 
  
    Issuance of common stock for cash, net 
     75,697  
     -  
     775  
     -  
     -  
     775 
  
    Reclassification to redeemable common stock 
     (75,697) 
     -  
     (799) 
     -  
     -  
     (799)
  
    Cashless exercise of warrants 
     4,781  
     -  
     -  
     -  
     -  
     - 
  
    Stock-based compensation 
     -  
     -  
     7,368  
     -  
     -  
     7,368 
  
    Loss on foreign currency translation 
     -  
     -  
     -  
     (100) 
     -  
     (100)
  
    Net loss 
     -  
     -  
     -  
     -  
     (30,008) 
     (30,008)
  
    Balance as of December 31, 2023 
     17,950,776  
     18  
     159,143  
     (799) 
     (121,022) 
     37,340